Prothena Corp. Plc (PRTA)

9.86
0.14 1.40
NASDAQ : Health Technology
Prev Close 10.00
Open 10.00
Day Low/High 9.77 / 10.23
52 Wk Low/High 8.63 / 15.91
Volume 182.98K
Avg Volume 265.50K
Exchange NASDAQ
Shares Outstanding 39.87M
Market Cap 389.48M
EPS -3.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
3 Stocks You Probably Never Heard Of Could Catch Fire Soon

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

Six charts showing signs of smart money footprints.

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

The biotech company plans to commercialize its treatment for AL amyloidosis, a disease that causes protein to build up in the blood.

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders

TheStreet Quant Rating: D (Sell)